On November 2, 2021, the Florida Department of Health’s Office of Medical Marijuana Use (OMMU), determined that Curaleaf Florida, LLC d/b/a Curaleaf (Curaleaf) dispensed medical marijuana products to qualified patients that reported a failed testing value of Aspergillus in violation of Rule 64ER20-9(2)(a)3., Florida Administrative Code. The contaminated products, LilacContinue Reading